GC Biopharma introduces candidates for treating blood coagulation disease

The company entered into an asset transfer agreement with Catalyst Biosciences to introduce drug candidates for a rare blood coagulation disease

Nassim Usman, CEO of Catalyst Biosciences(left) and Huh Eun-chul, CEO of GC Biopharma
Nassim Usman, CEO of Catalyst Biosciences(left) and Huh Eun-chul, CEO of GC Biopharma
Jae-Young Han 1
2023-03-02 10:58:46 jyhan@hankyung.com
Bio & Pharma

South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based drug development firm, in order to introduce drug candidates for a rare blood coagulation disease.

The Korean drug maker will acquire a total of three candidates, including MarzAA, which is currently in the global phase 3 clinical trials. GC Biopharma claims that MarzAA has demonstrated effectiveness and safety in previous clinical trials and is being developed as a subcutaneous injection formulation.

The company intends to continue conducting clinical trials on the candidate substances with the aim of launching a new drug. Previously, GC Biopharma successfully developed Green Mono and Greengene F for hemophilia, one of the blood clotting disorders.

"We will expand our efforts globally to improve the treatment options for patients suffering from various rare diseases, including rare blood clotting disorders," said Huh Eun-chul, CEO of GC Biopharma.

Write to Jae-Young Han at jyhan@hankyung.com
#GC Biopharma #Green Cross Corporation #Catalyst Biosciences #rare blood coagulation disease #MarzAA #korea gcbiopharma catalyst #gc catalyst biosciences

GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine

GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine

South Korea's GC Biopharma Corp. is set to regain the No. 1 spot in global production of chickenpox vaccines after earning qualification to enter the World Health Organization (WHO) procurement market with Barycela following its export hit Suduvax. This breakthrough is expected to heat up glob

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma headquarters  GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture specializing in orphan drugs, has received rare pediatric disease designation (RPDD) from the US Food and Drug Administrat

GC Biopharma, Sanofi to jointly market Plavix

GC Biopharma, Sanofi to jointly market Plavix

Plavix GC Biopharma Co. (formerly Green Cross Corp.) said on Monday it has entered into a joint sales partnership with Sanofi-Aventis Korea, the South Korean subsidiary of multinational pharmaceuticals company Sanofi, for Plavix 75 mg, an antiplatelet medication.The agreement calls for GC Bioph

GC Biopharma's Ochang facility gets WHO PQ certification

GC Biopharma's Ochang facility gets WHO PQ certification

GC Biopharma GC Biopharma Co.'s production facility in Ochang (North Chungcheong Province) secured a pre-qualification (PQ) certification from the World Health Organization (WHO).According to the company formerly known as GC Green Cross on Thursday, the 'integrated finished product facility' in
(* comment hide *}